Quantifying New Heart Muscle Cells

Key facts

Sponsor

Weill Medical College of Cornell University

Principal Investigator

Bernhard Kuhn, MD

Weill Medical College of Cornell University

Intervention

N15-thymidine(other)

Enrollment

30 enrolled

Eligibility

1 years · All sexes

Timeline

2015 – 2027

Study locations (1)

• Weill Cornell Medicine, New York, New York, United States

Collaborators

National Heart, Lung, and Blood Institute (NHLBI) · California Institute of Technology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tetralogy of Fallot

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT06668389
  Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
  The University of Hong Kong
• RECRUITINGNANCT06822400
  Investigation of Tetralogy of Fallot in Neonates
  Beijing Anzhen Hospital
• ACTIVE NOT RECRUITINGNCT06282926
  Role of 3D Echocardiography Knowledge-based Reconstruction in ACHD
  Guy's and St Thomas' NHS Foundation Trust
• RECRUITINGPHASE1NCT04713657
  Beta-blocker Administration for Cardiomyocyte Division
  Weill Medical College of Cornell University
• ACTIVE NOT RECRUITINGNCT05378386
  ALTERRA Post-Approval Study
  Edwards Lifesciences
• RECRUITINGNCT05122962
  Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
  Mayo Clinic
• RECRUITINGNCT05288894
  Repaired Tetralogy of Fallot Italian Registry
  Azienda Ospedaliero, Universitaria Ospedali Riuniti
• ACTIVE NOT RECRUITINGNANCT03983512
  PULSTA Transcatheter Pulmonary Valve Pre-Approval Study
  Taewoong Medical Co., Ltd.

See all trials for Tetralogy of Fallot →